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ABSTRACT
INTRODUCTION: The aim of this study is to evaluate the distribution of the most common comorbid con-
ditions associated with chronic temporomandibular disorders, and the pharmacological agents which play 
an integral role in the overall management of temporomandibular joint disorders. 
MATERIALS AND METHODS: A total of 23 articles are included in this comprehensive review of the rel-
evant studies on common comorbid conditions related to temporomandibular disorders. This review pro-
vides summarized clinical and online platform based analyses focused on the five most common comorbid 
conditions and their relevant pharmacological therapy.
RESULTS AND CONCLUSION: The majority of the studies show that comorbid conditions may include 
fibromyalgia, systemic myofascial pain and chronic fatigue syndrome, chronic headaches, migraine, heart 
arrhythmias, endometriosis, interstitial cystitis, irritable bowel syndrome, lower back pain, sleep disor-
ders - insomnia, autoimmune diseases, sleep apnea, noises and irritation in the ear, vulvodynia and mental 
disorders. The top comorbid conditions reported from people with TMJ syndrome, regardless of status are: 
anxiety, depression, insomnia, fatigue and pain.  
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INTRODUCTION
One of the main symptoms of temporomandib-
ular disorders (TMD) is pain localized in the area of 
the mandibular joint, masticatory muscles and other 
structures of the head and neck. Clarification of the 
exact source of the pain may pose a diagnostic chal-
lenge for clinicians, effective treatment of the disease 
and identification of the exact diagnosis. TMD is a 
major cause of pain with non-dental origin in the 
orofacial region. The incidence of TMD ranges up to 
12% of the population, the typical age range is be-
tween 20 to 40 years and is observed twice as com-
mon in women than men (23). Pain-related symp-
toms can vary from mild discomfort to debilitat-
ing pain, including severe limitations of masticato-
ry function (13,14). The most common and typical 
symptoms are myofascial pain, disk dislocations and 
disabilities, degenerative conditions like osteoarthri-
tis and osteoarthrosis, as well as autoimmune diseas-
es (2,18,20). 
DEFINITIONS
TMD is a complex disorder with possible etio-
pathogenetic perspective, the etiology is multifac-
torial and includes biological, genetic, behavioural, 
emotional, cognitive and psychosocial related fac-
tors. The treatment of TMD varies greatly depend-
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anxiolytics (41%) and muscle relaxants (40%). Near-
ly 60% of patients classified pain as with moderate to 
severe intensity; one-quarter of them pointed it as a 
factor influencing or terminating their employment 
and activity (12). Many of the associated conditions 
are over six times more likely to occur if the patient 
is diagnosed with TMD. Among the wide range of 
46 listed procedures used for the treatment of tem-
poromandibular disorders, the most effective ones 
for the group of the most-affected patients (91%) are 
the thermal therapies-hot/cold compresses on the fa-
cial area or hot tubs. Almost 40% of TMD patients 
have undergone one or more surgical procedures 
and almost all have undergone medication with dif-
ferent means. The results of these treatments are not 
unique. Although this study is potentially limited to 
the most severe cases it shows that TMDs represent 
a wide spectrum of disorders with different clinical 
manifestations, pathophysiology and related comor-
bid conditions. The complex nature of TMD demon-
strates the need for a broader interdisciplinary basic 
and clinical research and development of evidence-
based strategies for more effective diagnostics, pre-
vention and treatment of this chronic, debilitating 
diseases.
Comorbid conditions can be reliably and thor-
oughly identified and assessed in the real medical 
and dental clinical practice through an online net-
work real-time platform for the exchange of data 
which regularly introduces updated data about the 
condition of the patients, their history of illness and 
the treatment, side effects, symptoms, the quality of 
life and etc. According to a report in JAMA, struc-
tured quantitative data can be summarized for re-
search purposes. Online registration of data does not 
replace randomized placebo controlled trials, but it 
is a useful and modern form of information gather-
ing and monitoring of clinical trials under certain 
circumstances.
MAIN COMORBID CONDITIONS 
The data from the online platforms at this 
stage is valid mainly for the population of the Unit-
ed States. The platforms provide a wealth of informa-
tion about symptoms and medical treatment of pri-
mary temporomandibular joint syndrome and the 
comorbid conditions, such as that the ratio between 
ing on the competencies, the specialty and clinical 
experience of the treating specialist. This variabili-
ty in actual clinical practice is due to the paucity of 
evidence-based research results, and lack of consen-
sus about appropriate symptomatic or complex treat-
ment of the specific subclass of these diseases. Ad-
equate diagnosis and treatment of TMD is com-
pounded by the high incidence of specific signs and 
symptoms that may be associated with systemic dis-
eases and comorbid conditions - 85% of patients with 
TMD have complaints of different intensity and lo-
cation of pain in other parts of the body, they usually 
represent local or regional manifestations of chron-
ic, generalized muscle-skeletal pathologies such as 
fibromyalgia, systemic myofascial pain and chron-
ic fatigue syndrome. The comorbid conditions on 
the basis of clinical observations may include chron-
ic headaches, migraine, heart arrhythmias, endome-
triosis, interstitial cystitis, irritable bowel syndrome, 
low back pain, sleep disorders - insomnia, autoim-
mune diseases, sleep apnea, noises and irritation in 
the ear, vulvodynia and mental disorders. They are 
considered comorbid conditions because they are 
more commonly observed as individual symptoms 
than in combination of two or more. This in turn is 
an incentive for conducting research with respect to 
the elucidation of common mechanisms for all co-
morbid conditions (9). 
DATA ANALYSIS
A survey covering more than 6000 participants, 
shows the double increase of TMD in people with de-
pression (percentage ratio =2.1; 95% confidence in-
terval 1.5 to 3; P<.001) and 1.8 times increase of myo-
fascial pain in individuals with anxiety (percent-
age =1.8; 95% confidence interval 1.2 to 2.6; P<.001). 
Many of the comorbid conditions are more prevalent 
and are extremely specific for women. Long-term 
studies show that 50% to 90% of patients had pain re-
lief after conservative therapy. Multidisciplinary ap-
proach is the key to successful and sustainable treat-
ment of TMDs. The main objectives of initial therapy 
should focus on solving the problems of pain and or-
gan dysfunction. A TMJ Association, Ltd survey on 
1511 TMD diagnosed patients in the USA in a web-
based online platform shows that these patients are 
treated with anti-inflammatory drugs (73%), pain-
killers (56%), antidepressants (50%), opioids (48%), 
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primary TMD and TMD with diagnosed comorbid 
conditions is approximately 1 to 8. The top comorbid 
conditions reported from 1.306 people (6) with TMJ 
syndrome, regardless of status are: anxiety, depres-
sion, insomnia, fatigue and pain. The percentage dis-
tribution of these conditions is:
 Insomnia - 211 TMJ Syndrome patients report 
severe insomnia (22%), 299 patients - moder-
ate insomnia (31%), 250 patients - mild insom-
nia (26%), 203 TMJ Syndrome patients report 
no insomnia (21%). The most commonly used 
medications for the treatment of this condition 
are Trazodone, Zolpidem, Amitriptyline.
 Fatigue - 430 TMJ Syndrome patients report se-
vere fatigue (44%), 375 patients - moderate fa-
tigue (39%), 128 patients - mild fatigue (13%), 
40 TMJ syndrome patients report no fatigue 
(4%). The most commonly used medications to 
treat this condition are rest, Vitamin B Com-
plex, Modafinil. 
 Pain - 386 TMJ Syndrome patients report se-
vere pain (40%), 407 patients - moderate pain 
(42%), 142 patients - mild pain (15%), 36 TMJ 
Syndrome patients report no pain (4%). The 
most commonly used medications to treat this 
condition are Tramadol, Hydrocodone-Acet-
aminophen, Ibuprofen. 
 Anxious mood - 124 TMJ Syndrome patients 
report severe anxious mood (13%), 362 patients 
- moderate anxious mood (38%), 323 patients 
- mild anxious mood (34%), 151 TMJ Syn-
drome patients report no anxious mood (16%). 
The most commonly used medications to treat 
this condition are Clonazepam, Alprazolam, 
Lorazepam. 
 Depressed mood - 141 TMJ Syndrome patients 
report severe depressed mood (15%), 323 pa-
tients - moderate depressed mood (35%), 310 
patients - mild depressed mood (32%), 179 TMJ 
Syndrome patients report no depressed mood 
(19%). The most commonly used medications 
for the treatment of this condition are Dulox-
etine, Sertraline, Venlafaxine (6).
MOST COMMONLY USED 
MEDICATIONS 
The most commonly used medications to treat 
TMJ syndrome – as a primary or as a comorbid con-
dition are: Amitriptyline (Elavil), Tramadol (Ul-
tram) Gabapentin (Neurontin), Duloxetine (Cym-
balta) Diclofenac (Voltaren gel), Naproxen Naproxen 
(500), Trazodone (Desyrel) Hydrocodone-acetamin-
ophen (Vicodin) Pregabalin (Lyrica), Clonazepam 
(Klonopin) (6).
The national institutes of health, stress on the 
importance of the 2 keywords in the treatment ther-
apy: conservative and reversible. A growing amount 
of literature supports nonsurgical intervention for 
TMDs. As with other muscle/joint conditions, the 
treatment is directed towards unloading the struc-
tures and the management of the accompanying dis-
comfort. The American Academy of Oral and Max-
illofacial Surgeons (2012) states: “surgical procedure 
for internal disorder is indicated only when nonsur-
gical treatment is ineffective and pain or dysfunc-
tion are moderate to severe”. Johns Hopkins Insti-
tute of Health considers the following non-surgical 
approach to be needed for TMD treatment: pharma-
cological treatment: non-opioid analgesics and non-
steroidal anti-inflammatory drugs, low-dose tricy-
clic antidepressants, centrally acting skeletal muscle 
relaxants; reversible: oral appliances for patients with 
documented teeth grinding; physical therapy; be-
havior changes for the trigger factors that can cause 
TMD (consult a behavioral specialist for the bene-
fits), cognitive behavioral therapy for patients with 
co-existing depression and anxiety. Guidelines for 
the diagnosis and management of disorders involv-
ing the temporomandibular joint and related mus-
culoskeletal structures, approved by the American 
Association of Temporomandibular Joint Surgeons 
state that no surgical treatment should be consid-
ered for all patients with symptomatic internal dis-
order/osteoarthritis. (clinical and pathologic condi-
tion of disc displacement is internal disorder (ID), as 
well as the usual accompanying osteoarthritis (OA), 
also known as osteoarthrosis or degenerative joint 
disease). The reason for this focus is that the ID/OA 
is considered to be the most common cause of se-
vere TMJ pain and dysfunction for mild or moder-
ate pain and dysfunction, for which this treatment 
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alone is often enough. Patients with severe pain and 
dysfunction can also be treated non-surgically, but if 
there is not a visible reduction of the symptoms with-
in 2-3 weeks, surgical consultation is indicated. Non-
steroidal anti-inflammatory drugs (NSAIDs) act as 
support for pharmacological treatment of musculo-
skeletal disorders, where pain and inflammation are 
prominent features. Low dosage tricyclic antidepres-
sants are effective in controlling the pain of night-
time gnashing of teeth, when doses are adjusted to 
ensure improved sleep. After a psychiatric consulta-
tion, if it is found that clinical depression is an ag-
gravating factor, antidepressant medications may be 
useful as part of the treatment. The continued use of 
other drugs such as tranquilizers, muscle relaxants, 
sedatives and narcotic pain medications are rare-
ly mentioned. Narcotic pain medications are com-
monly used for a short period after the operation. If 
necessary, for extended periods of time, it is recom-
mended to consult a specialist in pain management 
(3,4,7,8,11,13,15,17,19,21,22,24,25,26,27).
CONCLUSION
Knowledge of comorbid conditions and its 
pharmacologic therapy can assist with management 
of some symptoms associated with TMDs. Medica-
tion in conjunction with appropriate physical thera-
py and definitive treatments can offer the more com-
plete approach to many problems. The most com-
mon classes of pharmacological agents used for the 
management of TMD and comorbid conditions are 
analgesics, anti-inflammatories, muscle relaxants, 
anxiolytics, antidepressants, anticonvulsants, etc. 
Each class of medication is specifically used for dif-
ferent disorders and the clinician must be familiar 
with the proper dosages indicated, and potential ad-
verse effects.
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